Myeloma
-
Taking Stock of CAR T-Cell Therapy
Five years after the FDA approved the first CAR T-cell therapy, use of the treatment has expanded to many patients with blood cancer.
by Kendall K. Morgan
-
The View From a CAR T-Cell Clinical Trial
After exhausting her treatment options, Ellen Reich got CAR T-cell treatment for multiple myeloma through a clinical trial.
by Pamela Rafalow Grossman
-
Forward Look
Crowdsourcing Support
After struggling to understand her treatment options for multiple myeloma, Jenny Ahlstrom started a virtual platform for patients to gather information about blood cancers.
by Allison Futterman
-
Forward Look
First CAR-T Cell Therapy Approved for Multiple Myeloma
Cellular immunotherapies can offer periods when people do not require treatment.
by Christina Bennett
-
More Data on COVID-19 Vaccination and Cancer
Studies indicate that many people with cancer have an antibody response to the vaccines, but this response may be reduced or absent in certain patients.
by Anna Goshua
-
Searching the Blood for Signs of Altered Immunity
The immune systems of people with blood cancer respond differently to infection with the coronavirus than the immune systems of people without cancer or with solid tumors.
by Kate Yandell
-
Multiple Myeloma: Choosing Your Path
New therapies provide hope and options for people as they monitor and manage this incurable blood cancer.
by Tara Haelle
-
Learning Medicare’s ABCDs
Medicare was established to help provide affordable health care coverage for older Americans. But Medicare beneficiaries with cancer can still face financial burdens related to their care.
by Kate Yandell
-
Policy Matters
Racial and Ethnic Disparities in Multiple Myeloma Clinical Trials
The AACR and the FDA presented joint recommendations that include broadening clinical trial eligibility and engaging the community in clinical trial recruitment.
by Kenneth C. Anderson, MD; Lola A. Fashoyin-Aje, MD, MPH; Nicole Gormley, MD; and Paul G. Kluetz, MD
-
Forward Look
Learning How to Prevent Multiple Myeloma
Irene Ghobrial on studying cancer precursors.
by Sue Rochman
